The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Factors that prevent the personalization of therapies in AML
Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, outlines some of the challenges associated with personalizing therapy in patients with acute myeloid leukemia (AML). Dr Fathi explains that obtaining a patient’s molecular signature is sometimes hindered by socioeconomic factors and result wait times. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy – Genentech, BMS/Celgene, Foghorn, Kite, Morphosys, Abbvie, Takeda, Ipsen, Forma, Amgen, Novartis, Astellas, Immunogen, Mablytics, EnClear, Orum, PureTech, Daiichi Sankyo, Pfizer Research funding – BMS/Celgene, Abbvie, Agios/Servier
